-- In a 14. col.ins. article it is reported that:
'US. Regulators are to consider a groundbreaking - but possibly controversial - new application to use an HIV medicine as a way to prevent healthy people from becoming infected with the lethal virus.
Gilead, the California-based pharma. gp., has filed with the FDA. for a new authorised "Indication" for "Pre-exposure prophylactic" - or prep - use of "Truvada", its pill that is currently the the back-bone of HIV treatment around the world.'
'... .
'However, it also risks undermining the effective use of Truvada for existing patients, weakening existing prevention efforts and could even trigger legal actions against the Co. from those currently without HIV who experience side-effects or who become infected.
'... .
'For those on low incomes in developing countries and with inadequate health insurance, including in the US., Truvada's preventive use could also create fresh ethical problems, with tensions between patients and those without HIV both seeking access to the medicine.'.

-- Source: Financial Times for dec.17/dec.18 2011. - Pharmaceuticals.
- Web: > World business, finance, and political news from the Financial Times - FT.com <